纳米鲁单抗

纳米鲁单抗（INN：namilumab；开发代号：MT203），或译那美芦单抗，是一种人单克隆抗体（IgG1 κ类），靶向粒细胞-巨噬细胞集落刺激因子（简称GM-CSF或CSF2），目前正在研究用于类风湿性关节炎和银屑病关节炎。^[1][2][3]纳米鲁单抗正在进行I期和II期临床试验，以确定该抗体在斑块型银屑病^[4]和类风湿性关节炎中的安全性、耐受性和初步治疗效用。^[5][6]

纳米鲁单抗

单克隆抗体
种类	完整抗体
目標	CSF2
臨床資料
ATC碼	未分配
识别信息
CAS号	1206681-39-1  Y
ChemSpider	none
UNII	MED485W763

纳米鲁单抗由武田制药国际公司开发并由Micromet Inc生产。^[3][7]

参考资料

1. World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 (PDF). WHO Drug Information. 2010, 24 (4).
2. Huizinga T, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E. Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA): Abstract Number: 969. Arthritis & Rheumatology. October 2015, 67.
3. Namilumab. Adis Insight. Springer Nature Switzerland AG. [2017-03-24].
4. Clinical trial number NCT02129777 for "Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis" at ClinicalTrials.gov
5. A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate. Adis Insight. Springer Nature Switzerland AG. [2017-03-24].
6. Clinical trial number NCT02379091 for "Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
7. Namilumab. Takeda clinical trials summary.